Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (Nasdaq: QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Quantum-Si’s benchtop protein sequencing platform, chemistry kits, and data analysis tools are evolving over time.
Recent Quantum-Si news has highlighted product launches such as the V4 Sequencing Kit, which the company reports improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The company has also announced a Version 3 Library Preparation Kit designed for lower protein input and detection of low-abundance proteins, along with data analysis enhancements that unlock detection of additional amino acids and improve peptide alignment and protein inference.
Investors and researchers can use this page to track updates on Quantum-Si’s Proteus platform development, including prototype sequencing milestones, technology roadmap disclosures, and plans related to amino acid coverage, controlled cleavage chemistry, and post-translational modification methods. Financial news items, such as quarterly earnings releases, capital raising transactions, and lease or other material agreements disclosed via Form 8-K, also appear in this feed.
In addition, the news stream captures corporate governance and human capital updates, including inducement grants under the company’s 2023 Inducement Equity Incentive Plan, investor conference participation, and Investor & Analyst Day events. Bookmark this page to review Quantum-Si’s official press releases and regulatory news in one place, with a focus on developments that shape the company’s proteomics technology, commercialization efforts, and capital markets activity.
Quantum-Si (Nasdaq: QSI) launched a Version 3 Library Preparation Kit and a suite of data analysis enhancements on December 22, 2025. The Version 3 kit requires 200 ng or less total protein input, a 100-fold improvement versus the prior kit, and internal validation shows detection of proteins with as little as 1–2 ng input (under 1% relative abundance in mixtures). The analysis updates add detection of methionine, improve peptide alignment and protein inference, and expand amino acid coverage to 15 amino acids. Combined with the Version 4 Sequencing Kit launched September 2025, the company says users should see improved analysis of scarce samples and low‑abundance biomarkers.
Quantum-Si (Nasdaq: QSI) announced that its Compensation Committee granted 39,920 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan. The grants were made as inducements pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on December 20, 2026, with the remaining 75% vesting in 12 equal quarterly installments thereafter, subject to continued employment and the RSU agreement and plan terms.
Quantum-Si (Nasdaq: QSI) summarized progress from its Investor & Analyst Day on November 19, 2025, outlining development milestones and timelines for the Proteus platform.
Key points: Proteus is on track for an end‑of‑2026 launch with an Early Access Program expected in summer 2026, planned coverage of 18 amino acids at launch, and product pricing to be announced in Q2 2026. An accelerated program aims to demonstrate detection of all 20 amino acids in 2026 with commercial capability on Proteus in 2027. The company unveiled a new controlled cleavage sequencing chemistry it says can enable billions of sequencing reads when combined with Proteus, and noted a suite of PTM methods for broad post‑translational modification analysis.
Quantum-Si (Nasdaq: QSI) held an Investor & Analyst Day on November 19, 2025 to present updates on the Proteus™ platform and the company’s technology pipeline.
Management reported completion of sequencing on a Proteus prototype, more than 50 sequencing runs across multiple prototypes, and early prototype data that the company says is meeting or exceeding the performance of its Platinum® Pro system. Presentations will describe a long-term roadmap to billions of reads, the path to detecting all 20 amino acids, a suite of post-translational modification (PTM) methods in development, and the path to Proteus commercial launch including timeline and key technical and commercial milestones.
Quantum-Si (Nasdaq: QSI) reported third quarter 2025 results and product progress on November 5, 2025. Q3 revenue was $552,000 with gross profit $194,000 (35% margin); nine‑month revenue was $2.0M with 52% gross margin. The company reported net loss of $35.7M in Q3 and adjusted EBITDA of -$20.1M. Total operating expenses rose to $40.0M in Q3. Quantum‑Si achieved successful sequencing on a prototype Proteus system and remains on track for a Proteus platform delivery in H2 2026. The company launched a version 4 Sequencing Kit in early September and expects a version 3 Library Prep Kit before year‑end 2025. Cash and investments were $230.5M, stated to fund operations into Q2 2028.
Quantum-Si (Nasdaq: QSI) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 at the Westin NY Grand Central in New York.
CEO Jeff Hawkins will take part in a Fireside Chat at 3:30 PM ET on November 20, 2025; Hawkins and CFO Jeff Keyes will be available for one-on-one investor meetings that day. A live and archived webcast will be posted in the Investors > Events & Presentations section of the Quantum-Si website.
Quantum-Si (Nasdaq: QSI) will report third quarter 2025 financial results on Wednesday, November 5, 2025. Management will host a conference call the same day at 4:30 PM ET to discuss results and provide a business update.
Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host the call. Investors may listen via the live webcast on the company's Investors website under Events and Presentations or register to receive a dial-in number and personalized PIN. An archived webcast will be available for replay after the event.
Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein detection, has announced an upcoming Investor & Analyst event scheduled for November 19, 2025 in New York City.
The event will feature presentations from key management team members, followed by a Q&A session. While the in-person event at the Hyatt Centric Times Square is by invitation, a live webcast will be available for virtual attendees from 10 AM to 12 PM ET.
Quantum-Si (Nasdaq: QSI), a proteomics technology company, has granted 17,033 restricted stock units (RSUs) to new employees as inducement awards under its 2023 Inducement Plan. The RSUs will vest over four years, with 25% vesting on September 20, 2026, followed by 12 quarterly installments, contingent on continued employment.
These equity awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and are specifically designed to attract new talent who were not previously Quantum-Si employees.
Quantum-Si (Nasdaq: QSI) has launched its new V4 Sequencing Kit, compatible with both Platinum® and Platinum® Pro instruments. The upgraded kit delivers an 85% increase in sequenceable peptides compared to the V3 version, featuring enhanced glycine recognition and improved alanine and serine detection capabilities.
Key advancements include the ability to sequence through proline-rich domains, expanded amino acid coverage, and improved sample mixture precision with 24-plex barcoding capabilities. The new kit particularly benefits antibody sequencing applications and complex mixture analysis in immunoprecipitation workflows.
FAQ
What is the current stock price of Quantum-Si Incorporated (QSI)?
What is the market cap of Quantum-Si Incorporated (QSI)?
